Gurbuz, M. Et Al. 2022. Trastuzumab +/- Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group. JOURNAL OF GASTROINTESTINAL CANCER , vol.53, no.2 , 282-288.

Gurbuz, M., Akkus, E., Sakin, A., Urvay, S., Demiray, A. G., Sahin, S., ... Sakalar, T.(2022). Trastuzumab +/- Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group. JOURNAL OF GASTROINTESTINAL CANCER , vol.53, no.2, 282-288.

Gurbuz, Mustafa Et Al. "Trastuzumab +/- Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group," JOURNAL OF GASTROINTESTINAL CANCER , vol.53, no.2, 282-288, 2022

Gurbuz, Mustafa Et Al. "Trastuzumab +/- Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group." JOURNAL OF GASTROINTESTINAL CANCER , vol.53, no.2, pp.282-288, 2022

Gurbuz, M. Et Al. (2022) . "Trastuzumab +/- Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group." JOURNAL OF GASTROINTESTINAL CANCER , vol.53, no.2, pp.282-288.

@article{article, author={Mustafa Gurbuz Et Al. }, title={Trastuzumab +/- Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group}, journal={JOURNAL OF GASTROINTESTINAL CANCER}, year=2022, pages={282-288} }